Neurocrine Biosciences (NASDAQ:NBIX) has tumbled 8.56% during the past week and has dropped 7.62% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 7.46%. Neurocrine Biosciences (NASDAQ:NBIX) has underperformed the index by 8.46% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Neurocrine Biosciences (NASDAQ:NBIX): The stock opened at $46.11 on Friday but the bulls could not build on the opening and the stock topped out at $46.77 for the day. The stock traded down to $44.08 during the day, due to lack of any buying support eventually closed down at $44.24 with a loss of -4.35% for the day. The stock had closed at $46.25 on the previous day. The total traded volume was 2,101,047 shares.
The company shares have dropped -9.44% from its 1 Year high price. On Nov 27, 2015, the shares registered one year high at $58.46 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $46.64 and the 200 Day Moving Average price is recorded at $44.48.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Lloyd-Smith Malcolm, officer (Chief Regulatory Officer) of Neurocrine Biosciences Inc, had unloaded 9,000 shares at an average price of $50 in a transaction dated on May 31, 2016. The total value of the transaction was worth $450,000.
Many analysts have stated their opinion on the company shares. BMO Capital initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) The shares have been rated Outperform. The rating by the firm was issued on April 7, 2016. Currently the company Insiders own 4.8% of Neurocrine Biosciences shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -24.89% . During last six month period, the net percent change held by insiders has seen a change of -24.89%.
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.